BioXcel Therapeutics Inc Q1 2021 Earnings Call Transcript - Thomson StreetEvents

BioXcel Therapeutics Inc Q1 2021 Earnings Call Transcript

BioXcel Therapeutics Inc Q1 2021 Earnings Call Transcript - Thomson StreetEvents
BioXcel Therapeutics Inc Q1 2021 Earnings Call Transcript
Published May 10, 2021
Published May 10, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of BTAI.OQ earnings conference call or presentation 10-May-21 12:30pm GMT

  
Report Type:

Transcript

Source:
Company:
BioXcel Therapeutics Inc
Ticker
BTAI.OQ
Time
12:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Jin Law - UBS Investment Bank, Research Division - Analyst : This is Rich calling in for Colin. A couple of questions from us. The -- we only saw the MD Anderson Basket Study presentation at the upcoming ASCO, and I believe you guys mentioned that you would present the prostate cancer in midyear, but seems to be delayed now, so just any reason REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 10, 2021 / 12:30PM, BTAI.OQ - Q1 2021 BioXcel Therapeutics Inc Earnings Call for that? And also a follow-up question on, you mentioned the cash position after 1Q at $194 million. When do you expect to do another raise to support commercialization of 501?


Question: Jin Law - UBS Investment Bank, Research Division - Analyst : Yes, that answers it.


Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : I have a couple. So first, we know you said you expect potential acceptance of your 501 NDA this month and we're right at the 60-day mark since your press release. So could you characterize any new interactions with the FDA that you might have specifically had on this NDA after submission? And the second question is, what are the latest levers you have for non-dilutive finance funding? And do you have any preference for geography, EU versus Japan or perhaps royalty deals in the U.S.?


Question: Anita Dushyanth - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Just a couple here. Can you talk about the enrollment rate in the TRANQUILITY expansion study? And also -- sorry, if I missed this one. Were you able to mention what the size of the sales force is for the commercialization of the 501?

Table Of Contents

BioXcel Therapeutics Inc at Bank of America NAPA Healthcare Conference Transcript – 2021-06-14 – US$ 54.00 – Edited Transcript of BTAI.OQ presentation 14-Jun-21 3:30pm GMT

BioXcel Therapeutics Inc Annual Shareholders Meeting Transcript – 2021-06-11 – US$ 54.00 – Edited Transcript of BTAI.OQ shareholder or annual meeting 11-Jun-21 1:00pm GMT

BioXcel Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript – 2021-06-09 – US$ 54.00 – Edited Transcript of BTAI.OQ presentation 9-Jun-21 3:40pm GMT

BioXcel Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript – 2021-05-25 – US$ 54.00 – Edited Transcript of BTAI.OQ presentation 25-May-21 6:00pm GMT

BioXcel Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript – 2021-05-11 – US$ 54.00 – Edited Transcript of BTAI.OQ presentation 11-May-21 12:45pm GMT

BioXcel Therapeutics Inc Q4 2020 Earnings Call Transcript – 2021-03-11 – US$ 54.00 – Edited Transcript of BTAI.OQ earnings conference call or presentation 11-Mar-21 1:30pm GMT

BioXcel Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript – 2021-01-14 – US$ 54.00 – Edited Transcript of BTAI.OQ presentation 14-Jan-21 1:20pm GMT

BioXcel Therapeutics, Inc. - Special Call Transcript – 2021-01-05 – US$ 54.00 – Edited Transcript of BTAI.OQ conference call or presentation 5-Jan-21 1:30pm GMT

BioXcel Therapeutics Inc Q3 2020 Earnings Call Transcript – 2020-11-12 – US$ 54.00 – Edited Transcript of BTAI.OQ earnings conference call or presentation 12-Nov-20 1:30pm GMT

BioXcel Therapeutics Inc Q2 2020 Earnings Call Transcript – 2020-08-14 – US$ 54.00 – Edited Transcript of BTAI.OQ earnings conference call or presentation 14-Aug-20 12:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "BioXcel Therapeutics Inc Q1 2021 Earnings Call Transcript" May 10, 2021. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q1-2021-BioXcel-Therapeutics-Inc-Earnings-Call-T14682776>
  
APA:
Thomson StreetEvents. (2021). BioXcel Therapeutics Inc Q1 2021 Earnings Call Transcript May 10, 2021. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q1-2021-BioXcel-Therapeutics-Inc-Earnings-Call-T14682776>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.